The epigenetic drugs space has witnessed a two-fold increase in Series A venture funding, with total deal value increasing to ...

Swiss contract development and manufacturing organization (CDMO) Lonza (VTX: LONN) has signed a long-term commercial supply ...

The latest restructuring will reduce by 20% its cash operating expenses by the third quarter of 2025, the company said. Bluebird bio, which has been raising going concern doubts for the past two years ...

Basel, Switzerland, 24 September 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today the signature of a long-term commercial supply ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

During a panel discussion at the National Society of Genetic Counselors meeting, genetic counselors discuss the risks and benefits of gene therapies.

周二，根据TD Cowen的最新更新，MaxCyte Inc. (NASDAQ:MXCT)股票维持买入评级。该公司的立场是在与MaxCyte管理团队会面后得出的，包括总裁兼首席执行官Maher Masoud和首席财务官Doug Swirsky。讨论重点关注了该公司专有细胞工程技术（称为SPL（鱿鱼蛋白连接）组合）的强大和不断扩大的产品组合。 TD Cowen强调了SPL组合被低估的价值，特别是随着 ...

MaxCyte Inc. (NASDAQ:MXCT) 根据TD Cowen的最新更新维持买入评级。该公司的立场是在与MaxCyte管理团队会面后得出的，包括总裁兼首席执行官Maher Masoud和首席财务官Doug Swirsky。讨论重点关注了该公司专有细胞工程技术（称为SPL（Squid Protein Ligation）组合）的强大和不断扩展的产品组合。 TD Cowen强调了SPL组合被 ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

This investor is excited about the transformational potential of one growth stock that he's been eyeing up for his portfolio.

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

An inherited blood disorder, sickle cell disease can be managed with several treatment options to reduce painful episodes and ...